Lymphoma Transplant-Related Trial Finder
Click on the headings below to view relevant trials for the condition listed.
Indolent Lymphoma: Relapsed/Refractory (8 trials)
-
Monoclonal Antibody Therapy before STM for Relapsed or Refractory Lymphoid Malignancies (FH 2361)
A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies -
Combination Chemotherapy + G-CSF + Plerixafor for Lymphoma Patients Undergoing Mobilization of Autologous PBSC (FH 2310)
Mobilization of Autologous Peripheral Blood Stem Cells (PBSC) in CD20+ Lymphoma Patients Using RICE, G-CSF (Granulocyte-Colony Stimulating Factor), and Plerixafor -
Bendamustine + Dexamethasone + Filgrastim for Peripheral Stem Cell Mobilization (FH 7176)
A Phase II Study of Bendamustine (B), Dexamethasone (D), and GCSF (G) for Peripheral Blood Hematopoietic Stem Cell Mobilization -
Iodine I 131 Monoclonal Antibody BC8 + Autologous SCT for Relapsed Lymphoma (FH 2238)
A Study Evaluating Escalating Doses of 131I-BC8 (anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies -
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients with High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia (FH 2241)
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients with High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia -
Bortezomib and Vorinostat Post ASCT for Non-Hodgkin Lymphoma (FH 2292)
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen -
Lenalidomide w/wo Rituximab for NHL or CLL Patients Previously Treated With Donor Stem Cell Transplant (FH 2467)
A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL or NHL with Lenalidomide alone or with Rituxima -
CD19-specific Donor T Cells for B Cell Malignancies After Allogeneic Transplant (FH 2494)
A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies at High Risk of Relapse After Allogeneic Hematopoietic Stem Cell Transplant
Aggressive Lymphoma: Relapsed/Refractory (10 trials)
-
Monoclonal Antibody Therapy before STM for Relapsed or Refractory Lymphoid Malignancies (FH 2361)
A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies -
Combination Chemotherapy + G-CSF + Plerixafor for Lymphoma Patients Undergoing Mobilization of Autologous PBSC (FH 2310)
Mobilization of Autologous Peripheral Blood Stem Cells (PBSC) in CD20+ Lymphoma Patients Using RICE, G-CSF (Granulocyte-Colony Stimulating Factor), and Plerixafor -
Bendamustine + Dexamethasone + Filgrastim for Peripheral Stem Cell Mobilization (FH 7176)
A Phase II Study of Bendamustine (B), Dexamethasone (D), and GCSF (G) for Peripheral Blood Hematopoietic Stem Cell Mobilization -
Autologous Stem Cell Transplant Followed By Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma (FH 1409)
A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Non-Myeloablative Allogeneic Stem Cell Transplantation for Patients with Relapsed or Refractory Lymphoma - A Multi-Center Trial -
Iodine I 131 Monoclonal Antibody BC8 + Autologous SCT for Relapsed Lymphoma (FH 2238)
A Study Evaluating Escalating Doses of 131I-BC8 (anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies -
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients with High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia (FH 2241)
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients with High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia -
Y-90-Ibritumomab Tiuxetan + Reduced-Intensity Allogeneic Transplant for Aggressive B-Cell Lymphoma (FH 2398)
A phase II trial of high-dose 90Y-Ibritumomab tiuxetan (anti-CD20) followed by fludarabine and low-dose total body irradiation and HLA-matched allogeneic hematopoietic transplantation for patients with relapsed or refractory aggressive B-cell lymphoma -
Bortezomib and Vorinostat Post ASCT for Non-Hodgkin Lymphoma (FH 2292)
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen -
Lenalidomide w/wo Rituximab for NHL or CLL Patients Previously Treated With Donor Stem Cell Transplant (FH 2467)
A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL or NHL with Lenalidomide alone or with Rituximab -
CD19-specific Donor T Cells for B Cell Malignancies After Allogeneic Transplant (FH 2494)
A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies at High Risk of Relapse After Allogeneic Hematopoietic Stem Cell Transplant
Hodgkin Lymphoma: Relapsed/Refractory (3 trials)
-
Monoclonal Antibody Therapy before STM for Relapsed or Refractory Lymphoid Malignancies (FH 2361)
A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies -
Bendamustine + Dexamethasone + Filgrastim for Peripheral Stem Cell Mobilization (FH 7176)
A Phase II Study of Bendamustine (B), Dexamethasone (D), and GCSF (G) for Peripheral Blood Hematopoietic Stem Cell Mobilization -
Iodine I 131 Monoclonal Antibody BC8 + Autologous SCT for Relapsed Lymphoma (FH 2238)
A Study Evaluating Escalating Doses of 131I-BC8 (anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies
Mantle Cell Lymphoma: Newly Diagnosed/Untreated (2 trials)
-
Combination Chemotherapy + G-CSF + Plerixafor for Lymphoma Patients Undergoing Mobilization of Autologous PBSC (FH 2310)
Mobilization of Autologous Peripheral Blood Stem Cells (PBSC) in CD20+ Lymphoma Patients Using RICE, G-CSF (Granulocyte-Colony Stimulating Factor), and Plerixafor -
Bortezomib and Vorinostat Post ASCT for Non-Hodgkin Lymphoma (FH 2292)
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen
Mantle Cell Lymphoma: Relapsed/Refractory (9 trials, 1 pending)
-
Monoclonal Antibody Therapy before STM for Relapsed or Refractory Lymphoid Malignancies (FH 2361)
A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies -
Combination Chemotherapy + G-CSF + Plerixafor for Lymphoma Patients Undergoing Mobilization of Autologous PBSC (FH 2310)
Mobilization of Autologous Peripheral Blood Stem Cells (PBSC) in CD20+ Lymphoma Patients Using RICE, G-CSF (Granulocyte-Colony Stimulating Factor), and Plerixafor -
Bendamustine + Dexamethasone + Filgrastim for Peripheral Stem Cell Mobilization (FH 7176)
A Phase II Study of Bendamustine (B), Dexamethasone (D), and GCSF (G) for Peripheral Blood Hematopoietic Stem Cell Mobilization -
Iodine I 131 Monoclonal Antibody BC8 + Autologous SCT for Relapsed Lymphoma (FH 2238)
A Study Evaluating Escalating Doses of 131I-BC8 (anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies -
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients with High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia (FH 2241)
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients with High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia -
Bortezomib and Vorinostat Post ASCT for Non-Hodgkin Lymphoma (FH 2292)
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen -
Lenalidomide w/wo Rituximab for NHL or CLL Patients Previously Treated With Donor Stem Cell Transplant (FH 2467)
A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL or NHL with Lenalidomide alone or with Rituximab -
CD19-specific Donor T Cells for B Cell Malignancies After Allogeneic Transplant (FH 2494)
A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies at High Risk of Relapse After Allogeneic Hematopoietic Stem Cell Transplant
Pending
-
Bortezomib + Rituximab for Mantle Cell Lymphoma s/p Stem Cell Transplant (FH 2620)
A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma Post Autologous Hematopoietic Cell Transplantation
T-Cell Lymphoma (5 trials)
-
Monoclonal Antibody Therapy before STM for Relapsed or Refractory Lymphoid Malignancies (FH 2361)
A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies -
Bendamustine + Dexamethasone + Filgrastim for Peripheral Stem Cell Mobilization (FH 7176)
A Phase II Study of Bendamustine (B), Dexamethasone (D), and GCSF (G) for Peripheral Blood Hematopoietic Stem Cell Mobilization -
Iodine I 131 Monoclonal Antibody BC8 + Autologous SCT for Relapsed Lymphoma (FH 2238)
A Study Evaluating Escalating Doses of 131I-BC8 (anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies -
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients with High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia (FH 2241)
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients with High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia -
Bortezomib and Vorinostat Post ASCT for Non-Hodgkin Lymphoma (FH 2292)
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen
Chronic Lymphocytic Leukemia: Relapsed/Refractory (5 trials)
-
Bendamustine + Dexamethasone + Filgrastim for Peripheral Stem Cell Mobilization (FH 7176)
A Phase II Study of Bendamustine (B), Dexamethasone (D), and GCSF (G) for Peripheral Blood Hematopoietic Stem Cell Mobilization -
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients with High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia (FH 2241)
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients with High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia -
Non-myeloablative Transplants for CLL and SLL (FH 1840)
Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial -
Lenalidomide w/wo Rituximab for NHL or CLL Patients Previously Treated With Donor Stem Cell Transplant (FH 2467)
A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL or NHL with Lenalidomide alone or with Rituxima -
CD19-specific Donor T Cells for B Cell Malignancies After Allogeneic Transplant (FH 2494)
A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies at High Risk of Relapse After Allogeneic Hematopoietic Stem Cell Transplant
Clinical Trial Finder beta 2 updated 5/8/13.